Literature DB >> 27759577

A case report of bullous pemphigoid associated with a melanoma and review of the literature.

Kyle T Amber1, Christine M Panganiban, Dorota Korta, Sebastien de Feraudy, Kristen M Kelly, Sergei A Grando.   

Abstract

The association of bullous pemphigoid with melanoma remains controversial and poorly understood. Recent studies report the presence of the bullous pemphigoid antigen, BP180, in melanoma cells, yet not normal melanocytes, suggesting an underlying mechanism for cases of melanoma-associated bullous pemphigoid. We report on an 88-year-old woman who showed a temporal relationship between the development of bullous pemphigoid and melanoma. The patient did not receive programmed death ligand 1 inhibitor therapy and improved rapidly following complete excision of her melanoma, with clobetasol, doxycycline, and niacinamide. We review the literature on the relationship between bullous pemphigoid and melanoma, and propose a mechanism underlying a melanoma-associated bullous pemphigoid.

Entities:  

Mesh:

Year:  2017        PMID: 27759577      PMCID: PMC5358921          DOI: 10.1097/CMR.0000000000000307

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  19 in total

1.  The association of bullous pemphigoid with cerebrovascular disease and dementia: a case-control study.

Authors:  Kathy Taghipour; Ching-Chi Chi; Angela Vincent; Richard W Groves; Vanessa Venning; Fenella Wojnarowska
Journal:  Arch Dermatol       Date:  2010-11

2.  Distribution of collagen XVII in the human brain.

Authors:  Allan Seppänen; Tiina Suuronen; Silke C Hofmann; Kari Majamaa; Irina Alafuzoff
Journal:  Brain Res       Date:  2007-05-06       Impact factor: 3.252

3.  Rapid direct determination of HLA-DQB1 * 0301 in the whole blood of normal individuals and cancer patients by specific polymerase chain reaction amplification.

Authors:  M Lu; W A Thompson; D A Lawlor; J D Reveille; J E Lee
Journal:  J Immunol Methods       Date:  1996-11-29       Impact factor: 2.303

4.  A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab.

Authors:  Giuliana Carlos; Rachael Anforth; Shaun Chou; Arthur Clements; Pablo Fernandez-Peñas
Journal:  Melanoma Res       Date:  2015-06       Impact factor: 3.599

5.  Serum anti-BPAG1 auto-antibody is a novel marker for human melanoma.

Authors:  Takashi Shimbo; Atsushi Tanemura; Takehiko Yamazaki; Katsuto Tamai; Ichiro Katayama; Yasufumi Kaneda
Journal:  PLoS One       Date:  2010-05-10       Impact factor: 3.240

6.  A population-based study of the association between bullous pemphigoid and neurologic disorders.

Authors:  Katherine E Brick; Chad H Weaver; Rodolfo Savica; Christine M Lohse; Mark R Pittelkow; Bradley F Boeve; Lawrence E Gibson; Michael J Camilleri; Carilyn N Wieland
Journal:  J Am Acad Dermatol       Date:  2014-08-29       Impact factor: 11.527

7.  Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls.

Authors:  L Büdinger; L Borradori; C Yee; R Eming; S Ferencik; H Grosse-Wilde; H F Merk; K Yancey; M Hertl
Journal:  J Clin Invest       Date:  1998-12-15       Impact factor: 14.808

8.  Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies.

Authors:  Shelley J E Hwang; Giuliana Carlos; Shaun Chou; Deepal Wakade; Matteo S Carlino; Pablo Fernandez-Penas
Journal:  Melanoma Res       Date:  2016-08       Impact factor: 3.599

9.  Pemphigoid and malignancy.

Authors:  R L Parsons; J A Savin
Journal:  Br J Cancer       Date:  1968-12       Impact factor: 7.640

10.  Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid.

Authors:  Kristen M Beck; Joanna Dong; Larisa J Geskin; Vincent P Beltrani; Richard G Phelps; Richard D Carvajal; Gary Schwartz; Yvonne M Saenger; Robyn D Gartrell
Journal:  J Immunother Cancer       Date:  2016-04-19       Impact factor: 13.751

View more
  7 in total

Review 1.  Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.

Authors:  Kyle T Amber; Dedee F Murrell; Enno Schmidt; Pascal Joly; Luca Borradori
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

2.  Efficacy and safety of tetracyclines for pemphigoid: a systematic review and meta-analysis.

Authors:  Xin-Xing Jin; Xue Wang; Ying Shan; Si-Zhe Li; Qun Xu; Hong-Zhong Jin; Ya-Gang Zuo
Journal:  Arch Dermatol Res       Date:  2021-03-28       Impact factor: 3.017

3.  Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma.

Authors:  Kyle T Amber; Manuel Valdebran; Yuxin Lu; Sebastien De Feraudy; Kenneth G Linden
Journal:  J Dtsch Dermatol Ges       Date:  2018-02-01       Impact factor: 5.584

4.  Lokalisiertes prätibiales bullöses Pemphigoid bei einer Patientin unter Pembrolizumab-Therapie wegen eines metastasierten Melanoms.

Authors:  Kyle T Amber; Manuel Valdebran; Yuxin Lu; Sebastien De Feraudy; Kenneth G Linden
Journal:  J Dtsch Dermatol Ges       Date:  2018-02       Impact factor: 5.584

Review 5.  Lichen planus pemphigoides: A unique form of bullous and lichenoid eruptions secondary to nivolumab.

Authors:  Rohan R Shah; Chinmoy Bhate; Amanda Hernandez; Chin Hung Ho
Journal:  Dermatol Ther       Date:  2022-03-15       Impact factor: 3.858

Review 6.  The Role of Collagen XVII in Cancer: Squamous Cell Carcinoma and Beyond.

Authors:  Virginia A Jones; Payal M Patel; Frederick T Gibson; Adriana Cordova; Kyle T Amber
Journal:  Front Oncol       Date:  2020-03-19       Impact factor: 6.244

7.  Melanoma is associated with an increased risk of bullous pemphigoid: a large population-based longitudinal study.

Authors:  Khalaf Kridin; Jennifer E Hundt; Ralf J Ludwig; Kyle T Amber; Dana Tzur Bitan; Arnon D Cohen
Journal:  Arch Dermatol Res       Date:  2021-03-09       Impact factor: 3.017

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.